| 2.725 0.387 (16.55%) | 03-27 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 3.83 |
1-year : | 4.47 |
| Resists | First : | 3.27 |
Second : | 3.83 |
| Pivot price | 2.48 |
|||
| Supports | First : | 2.48 |
Second : | 2 |
| MAs | MA(5) : | 2.38 |
MA(20) : | 2.53 |
| MA(100) : | 3.59  |
MA(250) : | 3.98 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 40.3 |
D(3) : | 34.3 |
| RSI | RSI(14): 50.6 |
|||
| 52-week | High : | 11 | Low : | 2 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ UPC ] has closed below upper band by 8.8%. Bollinger Bands are 53.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 17 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.29 - 3.3 | 3.3 - 3.32 |
| Low: | 2.47 - 2.48 | 2.48 - 2.5 |
| Close: | 2.7 - 2.72 | 2.72 - 2.75 |
Universe Pharmaceuticals INC, a pharmaceutical company, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. It offers products for the treatment of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. The company also distributes and sells third-party producers, including biomedical drugs, medical instruments, traditional Chinese medicine pieces products, and dietary supplements. Its customers include pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was incorporated in 2019 and is based in Ji'An, China. Universe Pharmaceuticals INC is a subsidiary of Sununion Holding Group Limited.
Wed, 18 Mar 2026
Universe Pharmaceuticals (UPC) CEO lists 3,467 Class B shares - Stock Titan
Wed, 18 Mar 2026
Universe Pharmaceuticals (UPC) director Yu Yongping files initial Form 3 - Stock Titan
Wed, 18 Mar 2026
Universe Pharmaceuticals (UPC) CFO Yang Lin files initial insider Form 3 - Stock Titan
Wed, 11 Feb 2026
Universe Pharmaceuticals INC Announces Effective Date of Dual-Class Share Structure - GlobeNewswire
Sat, 27 Dec 2025
UPC Stock Surges as Strategic Moves Drive Market Confidence - timothysykes.com
Fri, 26 Dec 2025
UPC Stock Surges Amid Strategic Announcements - StocksToTrade
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 1 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 0.6 (%) |
| Held by Institutions | 5.1 (%) |
| Shares Short | 9 (K) |
| Shares Short P.Month | 9 (K) |
| EPS | -8.07 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 99.63 |
| Profit Margin | -20.6 % |
| Operating Margin | -6.8 % |
| Return on Assets (ttm) | -2.7 % |
| Return on Equity (ttm) | -7.3 % |
| Qtrly Rev. Growth | -14.2 % |
| Gross Profit (p.s.) | 11.18 |
| Sales Per Share | 31.7 |
| EBITDA (p.s.) | -4.27 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -5 (M) |
| Levered Free Cash Flow | -10 (M) |
| PE Ratio | -0.34 |
| PEG Ratio | 0 |
| Price to Book value | 0.02 |
| Price to Sales | 0.08 |
| Price to Cash Flow | -0.31 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|